CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.) カタリスト・ファ―マシュ―ティカルズ

 CPRXのチャート


 CPRXの企業情報

symbol CPRx
会社名 Catalyst Pharmaceuticals Inc (カタリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カタリスト・ファーマシューティカル(Catalyst Pharmaceuticals Inc. )(旧名:Catalyst Pharmaceutical Partners Inc.)は、開発段階のバイオ医薬品会社である。同社は、希少な衰弱性疾患を患うの人々のための治療法の開発及び商品化に注力する。同社には、「Firdapse」、「CPP-109」及び「CPP-115」の3品目の開発中の薬剤がある。「Firdapse」は、ランバート摂食筋萎縮症候群(LEMS)及び先天性筋無力症候群(CMS)の治療に適応され、amifampridineのリン酸塩から構成される。「Firdapse」の第Ⅲ相試験は完了した。「CPP-109」は、γ-アミノ酪酸(GABA)アミノトランスフェラーゼ阻害剤であり、トゥレット症候群の治療に適応される。「CPP-115」は、GABAアミノトランスフェラーゼ阻害剤であり、複雑な部分発作、トゥレット症候群及びてんかん発作などの神経学的適応症の治療に適応される。   カタリスト・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。神経筋と神経疾患をタ―ゲットとして処方薬の開発と商業化に従事。筋力低下を特徴とする自己免疫疾患であるランバ―ト・イ―トン症候群の治療薬Firdapse、乳児けいれんの治療薬CPP-115、トゥレット症候群治療CPP-109の開発を行う。本社はフロリダ州。   Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
本社所在地 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 USA
代表者氏名 Patrick James McEnany パトリック・ジェームス・マッケナニー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 305-529-2522
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 21人
url www.catalystpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cprx
adr_tso
EBITDA EBITDA(百万ドル) -22.05182
終値(lastsale) 3.39
時価総額(marketcap) 347811484.62
時価総額 時価総額(百万ドル) 339.60350
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 271.19460
当期純利益 当期純利益(百万ドル) -21.23038
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $11.7M. Higher net loss reflects reasear increase of 32% to $6.4M (expense) General and administrative - Balancing increase of 57% to $4.1M (expense) Stock-based Compensation in SGA increase of 23% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.11.

 CPRXのテクニカル分析


 CPRXのニュース

   Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.4% Higher  2021/12/19 08:19:19 ETF Daily News
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)s stock price traded up 2.4% during mid-day trading on Friday . The company traded as high as $6.90 and last traded at $6.88. 2,192 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,217,669 shares. The stock had previously closed at $6.72. Separately, HC [] The post Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.4% Higher appeared first on ETF Daily News .
   Fisher Asset Management LLC Buys Shares of 201,801 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)  2021/12/18 10:58:42 Dakota Financial News
Fisher Asset Management LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 201,801 shares of the biopharmaceutical companys stock, valued at approximately $1,070,000. Fisher Asset Management LLC owned 0.20% of []
   Gary Ingenito Sells 3,612 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock  2021/12/08 23:04:43 Dakota Financial News
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 3,612 shares of the firms stock in a transaction on Tuesday, December 7th. The shares were sold at an average price of $6.99, for a total transaction of $25,247.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Shares []
   Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan  2021/12/06 12:00:00 Intrado Digital Media
CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst''s FIRDAPSE ® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").
   If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year Ago, Here''s How Much You''d Have Now  2021/11/30 23:17:35 Benzinga
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalysts Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the companys Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019. In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapses label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.
   If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year Ago, Here''s How Much You''d Have Now  2021/11/30 23:17:35 Benzinga
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalysts Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in recent years came in 2018 when the companys Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan in 2019. In early 2020, Catalyst aggressively expanded its sales team to help monetize Firdapse and the company is actively undergoing trials to potentially expand Firdapses label to muscle-specific kinase myasthenia gravis (MuSK-MG) and other indications.
   The Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Metrics You Need To Know Right Now  2021/11/25 12:00:00 Stocks Register
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.10% to the previous days close as strong demand from buyers drove the stock to $7.38. Actively observing the price movement in the last trading, the stock closed the session at $7.30, falling within a range of $7.18 The Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Metrics You Need To Know Right Now Read More »
   Analysts Anticipate Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Will Post Earnings of $0.11 Per Share  2021/11/20 19:04:44 Dakota Financial News
Brokerages expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will report earnings of $0.11 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $0.10 to $0.11. Catalyst Pharmaceuticals also posted earnings of $0.11 per share in the same quarter last year. The firm […]
   What Could Change After Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Gains 56.01% From The High-Point?  2021/11/20 15:30:00 Marketing Sentinel
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)s traded shares stood at 0.59 million during the last session, with the companys beta value hitting 1.33. At the close of trading, the stocks price was $7.32, to imply an increase of 0.27% or $0.02 in intraday trading. The CPRX shares 52-week high remains $7.58, putting it -3.55% down since that What Could Change After Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Gains 56.01% From The High-Point? Read More »
   Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Expected to Announce Earnings of $0.11 Per Share  2021/11/18 15:14:44 Transcript Daily
Wall Street analysts expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce earnings per share (EPS) of $0.11 for the current quarter, according to Zacks. Four analysts have issued estimates for Catalyst Pharmaceuticals earnings. The highest EPS estimate is $0.11 and the lowest is $0.10. Catalyst Pharmaceuticals also posted earnings of $0.11 per share during the []
   Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Raised by Geode Capital Management LLC  2021/11/07 10:00:41 Dakota Financial News
Geode Capital Management LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,864,633 shares of the biopharmaceutical companys stock after buying an additional 97,768 shares during the quarter. Geode Capital Management LLC owned approximately 1.81% of Catalyst []
   Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Caxton Associates LP  2021/10/30 15:16:45 Dakota Financial News
Caxton Associates LP increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 74.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,023 shares of the biopharmaceutical companys stock after acquiring an additional 18,431 shares during the period. []
   Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021  2021/10/25 12:03:00 Intrado Digital Media
The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST
   Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?  2021/10/08 12:58:44 FXNews24
Catalyst Pharmaceutical CPRX shares soared 6.9% in the last trading session to close at $6.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stocks 21% gain over the past four weeks. Shares of Catalyst Pharmaceuticals have been surging consistently, following positive [] The post Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
   The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs  2021/10/08 11:31:17 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug collaboration with Nuemora) Angion Biomedica Corp. (NASDAQ: ANGN ) Applied DNA Sciences, Inc. (NASDAQ: APDN ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Avenue Therapeutics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カタリスト・ファ―マシュ―ティカルズ CPRX Catalyst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)